Denali Therapeutics Inc. DNLI Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s stock-based comp?
- Denali Therapeutics Inc. (DNLI) reported stock-based comp of $23.09M in Q1 2026.
- How has Denali Therapeutics Inc.'s stock-based comp changed year-over-year?
- Denali Therapeutics Inc.'s stock-based comp decreased by 8.2% year-over-year, from $25.16M to $23.09M.
- What is the long-term trend for Denali Therapeutics Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s stock-based comp has grown at a 4.0% compound annual growth rate (CAGR), from $85.25M to $99.63M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.